NGS analysis of one PSTT and one ETT sample identified a TP53 mutation in PSTT, as well as missense mutations in tumour suppressors APC and SMAD4 in both PSTT and ETT (Öz Atalay et al., 2023). The gene discussed is TP53; the disease is neoplasm.